NPM1 and myelodysplastic syndrome: For borderline cases of MDS and AML, with blast counts nearing the 20% cutoff, NGS can further support the AML diagnosis if certain molecular findings, such as mutations in the NPM1, FLT3 and CEBPA genes, are detected.